Century Therapeutics, Inc. (IPSC) is a Healthcare stock trading at $2.06 (as of 2026-08-21), with a market capitalization of $373.92M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Century Therapeutics develops allogeneic, iPSC-derived cell therapies (CAR-iNK and CAR-iT) for solid tumor and hematological cancers, and it makes money primarily through clinical development progress that can translate into revenue through collaborations.
The company’s profit potential is driven by whether its allogeneic iPSC-derived CAR-iNK and CAR-iT candidates show durable clinical efficacy and safety signals in trials, since operational KPIs are tied to response rates and trial patient outcomes.
Business quality (Weak): Strong focus on differentiated allogeneic iPSC-based cell therapy targets (CD19 for CNTY-101, CD133 plus EGFR for CNTY-103, and CD19 plus CD79b for CNTY-102), but near-term fundamentals show losses (operating margin -33.1) and collaboration revenue is shown as 0.0 in the provided segment candidates.
| Price | $2.06 |
| Market Cap | $373.92M |
| Price / Book | 1.61 |
| Price / Sales | 1.14 |
| FCF Yield | -50.0% |
| Revenue (TTM) | $109.16M |
| Net Margin | -8.8% |
| Revenue Growth (YoY) | 1556.8% |
| EPS Growth (YoY) | -91.3% |
| FCF Growth (YoY) | -5.0% |
| Altman Z-Score | -0.75 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | RA CAPITAL MANAGEMENT, L.P. ($40.13M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Brent Pfeiffenberger |
| Employees | 140 |
| Country | US |
| IPO Date | 2021-06-18 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.